ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Conference On Delayed Consequences Of Cancer Therapy Scheduled Jan. 9-11

January 3, 1975

How NCI Would Apportion New Round Of budget Cuts- 1980 $17 Million, 1981 $42.7 Million

April 11, 1980

AACR honors Five With Awards Next Month

April 2, 1993

NCAB Study Core Guideline Revisions; Final Decision To Await New Division BSC

May 23, 1980

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Group Chairmen Accept Most Changes In Terms Of Award, Object To CTEP Adjustments

December 2, 1988